Mozobil Solution For Injection 20Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Mozobil: Solution for injection (20mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

PLERIXAFOR (pler IX a fore) helps your body increase the amount of white blood cells in the blood. It is used to increase white blood cells before a stem cell transplant.

In-Depth Information
Select a Medication

Mozobil 24mg/1.2ml Solution for Injection

NDC: 584680140
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Peripheral Blood Stem Cell (PBSC) Mobilization

Storage Information
Discard unused portion. Do not store for later use.
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Mozobil 24mg/1.2ml Solution for Injection

Reported Side Effects for Mozobil 24mg/1.2ml Solution for Injection

Skin Irritation Incidence:
<34.0%*
Severity: MILD
Onset: EARLY
Skin Rash Incidence:
<34.0%*
Severity: MILD
Onset: EARLY
Paresthesias Incidence:
<34.0%*
Severity: MILD
Onset: DELAYED
Muscle And/Or Bone Pain Incidence:
<5.0%*
Severity: MILD
Onset: EARLY
Feeling Sick Incidence:
<5.0%*
Severity: MILD
Onset: EARLY
Hypoxia Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Hypoesthesia Incidence:
<5.0%*
Severity: MILD
Onset: DELAYED
Bruise Incidence:
<34.0%*
Severity: MODERATE
Onset: EARLY
Skin Redness Incidence:
<5.0%*
Severity: MODERATE
Onset: EARLY
Anaphylactoid Reactions Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Vomiting Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Fainting Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Bleeding Incidence:
<34.0%*
Severity: MODERATE
Onset: EARLY
Stomach Pain Incidence:
<5.0%*
Severity: MILD
Onset: EARLY
Dry Mouth Incidence:
<5.0%*
Severity: MILD
Onset: EARLY
Hives Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Itching Incidence:
<34.0%*
Severity: MILD
Onset: RAPID
Postural Low Blood Pressure Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Severe Allergy Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Low Blood Pressure Incidence:
<1.0%*
Severity: MODERATE
Onset: RAPID
Constipation Incidence:
<5.0%*
Severity: MODERATE
Onset: DELAYED
Excessive Sweating Incidence:
<5.0%*
Severity: MILD
Onset: DELAYED
Headache Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Loose Stools Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Upset Stomach Incidence:
<5.0%*
Severity: MILD
Onset: EARLY
Shortness Of Breath Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Upset Stomach Incidence:
1.0%*
Severity: SEVERE
Onset: EARLY
Gas Incidence:
7.0%*
Severity: MILD
Onset: EARLY
Inability To Sleep Incidence:
7.0%*
Severity: MILD
Onset: EARLY
High White Blood Cells Incidence:
>10.0%*
Severity: MILD
Onset: DELAYED
Lightheadedness Incidence:
11.0%*
Severity: MILD
Onset: EARLY
Joint Pain Incidence:
13.0%*
Severity: MILD
Onset: DELAYED
Tired Incidence:
27.0%*
Severity: MILD
Onset: EARLY
Injection Site Reaction Incidence:
34.0%*
Severity: MILD
Onset: RAPID
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Mozobil

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5